The Antitumor Assessment Core Facility was established in 2003 to provide expert support for early discovery of effective antitumor agents and therapeutics. The Core provides resources, professional and technical expertise and advisory services related to the evaluation of agents with potential therapeutic activity, and works closely with investigators to establish in vivo mouse models for the design and execution of pharmacokinetic, toxicity and In vivo efficacy studies. As such, the Core provides a major vehicle to facilitate pre-clinical studies and is a major contributor to the translational mission of the Center. The Core also determines the best formulation, administration route, and treatment schedule for each new compound, either alone or in combination with other agents. The Core helps investigators to design and plan their experiments, prepare animal protocols and grant applications involving animal studies, and analyzes and summarizes data for publication. Importantly, the Core acts as a central coordinator for studies involving support from several core facilities (including Animal Imaging, Comparative Pathology, Tissue Procurement Service, Analytical Pharmacology, Organic Synthesis, Microarray, Radiation Facility, and Cytology) so that studies are carried out properly and in a time- and cost-efficient manner. The services and collaborative work provided by the Antitumor Assessment Core has supported the research of 56 investigators from 9 programs. A particularly exciting example of the work supported is: in 2010 the Core provided support services that were used by Dr. Charles Sawyer's group (ET and CBEP Programs) to develop ARN-509, an Androgen Receptor (AR) inhibitor targeting castration-resistant prostate cancer (CRPC), the most advanced form of this disease. This study has led to a Phase l/ll Clinical Trial currently ongoing at MSKCC. The Core undertook all the animal studies performed at MSKCC for this work.

Public Health Relevance

The Antitumor Assessment Core Facility provides support for the evaluation of effective antitumor agents and therapeutics and thereby directly advances the translational research activities of Memorial Sloan- Kettering Cancer Center.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sloan-Kettering Institute for Cancer Research
New York
United States
Zip Code
Orlow, I; Satagopan, J M; Berwick, M et al. (2015) Genetic factors associated with naevus count and dermoscopic patterns: preliminary results from the Study of Nevi in Children (SONIC). Br J Dermatol 172:1081-9
Carey, Bryce W; Finley, Lydia W S; Cross, Justin R et al. (2015) Intracellular ?-ketoglutarate maintains the pluripotency of embryonic stem cells. Nature 518:413-6
Mosher, C E; Given, B A; Ostroff, J S (2015) Barriers to mental health service use among distressed family caregivers of lung cancer patients. Eur J Cancer Care (Engl) 24:50-9
Navi, Babak B; Reiner, Anne S; Kamel, Hooman et al. (2015) Association between incident cancer and subsequent stroke. Ann Neurol 77:291-300
Xu, Zhe; Wu, Chaochao; Xie, Fang et al. (2015) Comprehensive quantitative analysis of ovarian and breast cancer tumor peptidomes. J Proteome Res 14:422-33
Xu, Hong; Cheng, Ming; Guo, Hongfen et al. (2015) Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody. Cancer Immunol Res 3:266-77
Gondo, Tatsuo; Poon, Bing Ying; Matsumoto, Kazuhiro et al. (2015) Clinical role of pathological downgrading after radical prostatectomy in patients with biopsy confirmed Gleason score 3 + 4 prostate cancer. BJU Int 115:81-6
Ripley, R Taylor; McMillan, Robert R; Sima, Camelia S et al. (2014) Second primary lung cancers: smokers versus nonsmokers after resection of stage I lung adenocarcinoma. Ann Thorac Surg 98:968-74
Ye, Jiangbin; Fan, Jing; Venneti, Sriram et al. (2014) Serine catabolism regulates mitochondrial redox control during hypoxia. Cancer Discov 4:1406-17
Lu, Zhigang; Xu, Jin; Xu, Mingming et al. (2014) Morphine regulates expression of *-opioid receptor MOR-1A, an intron-retention carboxyl terminal splice variant of the *-opioid receptor (OPRM1) gene via miR-103/miR-107. Mol Pharmacol 85:368-80

Showing the most recent 10 out of 836 publications